Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

At first, an overactive bladder, or OAB, may turn your world upside down, but with proper management and a few day-to-day changes, you can find simple ways to adjust to a new lifestyle and even ...

Gemtesa is approved for men with overactive bladder symptoms who are receiving pharmacologic treatment for benign prostatic hyperplasia.

A great sex life and a good night's sleep don't have to be a thing of the past when you have OAB. Simple lifestyle and diet changes can really help you successfully manage overactive bladder.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

根据住友制药美国公司 (SMPA) 发布的新闻稿，FDA 批准 vibegron (Gemtesa；住友制药美国公司)，这是一种每日服用一次的 β-3 (β 3 ) 肾上腺素能受体激动剂，用于治疗患有膀胱过度活动症 (OAB) ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA ...